Please note…

You are now on the ey.com Suomi site. To return to the ey.com United States site or other country site, click on the Suomi (suomi) link on the upper right of this page, and select your preferred country site.

x
Skip to main navigation

Ernst & Young Global Biotechnology Center - Ernst & Young - Suomi

  • Jaa

Commitment and experience for changing times

More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world. But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges. Ernst & Young has been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry. We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals. So it’s not surprising that we serve more biotech companies than any other professional services firm.

Through the Ernst & Young’s Global Life Science Center, we bring together a worldwide team of industry professionals to help you achieve your potential — a team with deep experience in providing assurance, tax, transaction and advisory services specific to biotechnology companies around the globe. It’s a team that works to anticipate market trends and their implications, so you get practical advice on the right way forward for your organization. We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues specific and often unique to the biotech sector, as well as our Biotechnology Industry Annual Report, Beyond Borders (pdf, 1.8mb) , now in its 24th year.

Whether it’s raising capital, forming the right alliances, improving operations, expanding globally or gaining insights into the market, we can give you a clear perspective on how to drive value in today’s complex, competitive and risk-driven environment.

Accounting for business combinations: implications of Statement 141(R) for life sciences

The life sciences industry is witnessing an uptick in M&A activity. New changes in accounting rules could have a significant impact on the way in which transactions are structured as well as on an acquirer’s future earnings, financial metrics and compliance with debt covenants. This publication (pdf, 235.4kb) discusses the implications of the new rules, which apply to transactions with closing dates on or after 1 January 2009.

Accounting for clinical trials

Clinical development has always been expensive and risky. Today’s economy has only fueled these risks, as many firms reprioritize their pipelines and increase their reliance on clinical research organizations (CROs) to cut costs. In this bio*link, we summarize common accounting issues related to clinical activities (pdf, 142kb) and provide examples of good internal controls. We also offer useful information to help benchmark your internal controls against peers.

The top 10 business risks affecting life sciences companies

As industry regulations become more stringent, government and private insurers are placing unprecedented pressures on life sciences companies to demonstrate value for the products they develop. Not surprisingly, this challenge topped the list of the 10 most pressing risks facing the life sciences industry in 2009. Read the press release and report for steps which can be taken now to address top risks (pdf, 4.6mb) .

Pulse of the industry 2009: medtech review

Medtech emerged from the recession relatively healthy, but long-term challenges remain: a funding drought and an uncertain global regulatory and reimbursement environment. What’s in store for the medtech industry? In our latest report, we evaluate the industry’s performance — financial, financing and transaction activity — and provide not-to-be-missed insights from leading medtech organizations.

Lessons from change: the life sciences industry

How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment.

Woman looking through window in office
Back to top